

Performance in Delivering Qtr 2 2022-23

Id	Research Ethics Committee Reference Number	Integrated Research Application System Number	Name of Trial	Target Number Of Patients Agreed?	Minimum Number Of Patients Agreed (Enter Same In Both If Only One Number)	Maximum Number Of Patients Agreed (Enter Same In Both If Only One Number)	Target Date To Recruit Patients Agreed?	Date Agreed to recruit target number of patients	Total Number Of Patients Recruited At The Agreed Target Date	Date That The Trial Closed To Recruitment	Total Number Of Study Participants Recruited	Reason For Closure Of Trial	Comments
< Back													
61570	18/EM/0298	251419	A Phase 3b, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of TRC101 in Delaying Chronic Kidney Disease Progression in Subjects with Metabolic Acidosis	Number Agreed	1	1	Date Agreed	31/12/2021	1	08/11/2021	1	Recruitment Finished	
61571	19/NW/0673	270097	A PHASE 2B, DOUBLE-BLIND, RANDOMIZED, PLACEBO-CONTROLLED, MULTICENTER, DOSE RANGING STUDY TO EVALUATE THE EFFICACY AND SAFETY PROFILE OF PF 06700841 IN PARTICIPANTS WITH ACTIVE SYSTEMIC LUPUS ERYTHEMATOSUS (SLE)	Number Agreed	2	2	Date Agreed	02/02/2019	1	08/09/2022	1	Recruitment Finished	Logistical issues with couriers and samples, PI didn't want to recruit 2nd patient until Sponsor had sorted out issues, then study closed.